



US005455279A

United States Patent [19][11] **Patent Number:** **5,455,279****Lipton**[45] **Date of Patent:** **Oct. 3, 1995**[54] **REGIMEN METHOD OF MEDIATING NEURONAL DAMAGE USING NITROGLYCERINE**[75] Inventor: **Stuart A. Lipton**, Newton, Mass.[73] Assignee: **The Children's Medical Center Corporation**, Boston, Mass.[21] Appl. No.: **25,028**[22] Filed: **Mar. 2, 1993****Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 949,342, Sep. 22, 1992, Pat. No. 5,234,956, which is a continuation of Ser. No. 688,965, Apr. 19, 1991, abandoned.

[51] **Int. Cl.**⁶ **A61K 31/13; A61K 31/045; A61K 31/04**[52] **U.S. Cl.** **514/742; 514/724**[58] **Field of Search** **514/724, 668, 514/742**[56] **References Cited****U.S. PATENT DOCUMENTS**4,513,137 4/1985 Koser et al. 546/14
4,806,543 2/1989 Choi 514/464
5,091,391 2/1992 Aizenman et al. 514/311**FOREIGN PATENT DOCUMENTS**

WO91/02810 8/1990 WIPO .

OTHER PUBLICATIONS*Choi, *Neuron* 1:623 (1988).
Rothman et al., *Trends in Neurosci.* 10:299 (1987).
Meldrum et al., *Trends in Pharm. Sci.* 11:379-387 (1990).
Weiss et al., *Science* 247:1474 (1990).
Garthwaite et al., *Trends in Neurosci.* 14:60-67 (1991).
Hope et al., *Proc. Natl. Acad. Sci. USA* 88:2811-2814 (1991).
Aizenman et al., *Neuron* 5:8411-(1990).
Majewska et al., *Brain Res.* 537:328-332 (1990).
Levy et al., *Neurosci. Letters* 110:291-296 (1990).
Sucher et al., *Neuropharmacology and Neurotoxicity* 1:29-32 (1990).
Seubert, *Brain Research* 492:366-370 (1990).
Sernagor, *Neuron* 2:1221-1227 (1989).
Goldberg et al., *J. Pharm. Exp. Therapeutics* 245:1081-1087 (1988).
Davenport et al., *Eur. J. Pharm.* 154:73-78 (1988).
Choi et al., *J. Pharmacol. and Exp. Therapeutics* 242:713-720 (1987).
Garthwaite et al., *Neuroscience* 26:321-326 (1988).
Merck Index, 9th Edition, pp. 858-859 #6429 (1976).
Majewska et al., *Society For Neuroscience Abstracts*, vol. 15, p. 1167, No. 463.15 (1989).
Aizenman et al., *Neuron* 2:1257-1263 (1989).
Choi, *Neuron* 1:623-634 (1988).
Lipton et al., "A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds," *Nature*, 364:626-632, 1993.
Stamler, "Biochemistry of Nitric Oxide and Its Redox-Activated Forms," *Science*, 258:1898-1902, 1992.Lipton and Stamler, "Action of Redox-Related Congeners of Nitric Oxide at the NMDA Receptor", *Neuropharmacology*, 33:1229-1233, 1994.Stueher et al., *FASEB J.* 5:98-103, 1991.Lei et al., *Neuron* 8:1087-1099, 1992.Gallop et al., "Is the antioxidant, anti-inflammatory putative new vitamin, PQQ, involved with nitric oxide in bone metabolism?", *Connective Tissue Research* 29:153-161, 1993.Beckman, J., "The double-edged role of nitric oxide in brain function and superoxide-mediated injury," *J. Dev. Physiol.* 15:53-59 1991.Beckman, et al., "Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide," *Proc. Nat'l Acad. Sci. USA* 87:1620-1624, 1990.Cross, et al., "The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils", *Biochem. J.* 237:111-116 1986.Dawson, et al., "Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures," *J. Neurosci.* 13:2651-2661, 1993.Holland, et al., "Mechanism of Action of the Hypoglycemic Agent Diphenyleneiodonium," *J. Biol. Chem.* 248:6050-6056, 1973.Huang, et al., "Effects of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase", *Science* 265:1883-1885, 1994.Ignarro, L., "Nitric Oxide: A novel signal transduction mechanism for transcellular communication," *Hypertension* 16:477-483, 1990.*Primary Examiner*—Marianne M. Cintins
Assistant Examiner—T. J. Criares
Attorney, Agent, or Firm—Fish & Richardson[57] **ABSTRACT**Disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric-oxide or related redox species, in a concentration effective to effect neuroprotection. Also disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric oxide (or a related redox species such as NO³¹ or NO⁺ equivalent), or a physiologically concentration effective to cause such neuroprotection.